Solventum
SOLV
$79.25
-2.53%
Solventum Corporation is a healthcare company that develops, manufactures, and commercializes solutions leveraging material science, data science, and digital capabilities across MedSurg, Dental Solutions, and Health Information Systems segments. As a spin-off from 3M, it holds a distinct position as a diversified healthcare technology player with established brands in wound therapy, dental orthodontics, and clinical documentation software. The current investor narrative centers on its ability to stabilize revenue after a post-spin decline, improve profitability through operational efficiencies, and capitalize on its digital health platforms to drive long-term growth, with recent analyst upgrades reflecting optimism about its turnaround trajectory.…
SOLV
Solventum
$79.25
SOLV 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Solventum's 12-month outlook, with a consensus price target around $83.38 and implied upside of +5.2% versus the current price.
Average Target
$83.38
0 analysts
Implied Upside
+5.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$60 - $100
Analyst target range
Solventum is covered by 13 analysts, with a consensus recommendation of 'buy' and an average target price of $83.38. The current price of $81.31 implies a modest upside of +2.55% to the average target. The consensus leans bullish, with a mean recommendation of 2.33 (where 1 is strong buy and 5 is sell). The target price range spans from a low of $60.00 to a high of $100.00, indicating significant uncertainty. The high target of $100 assumes successful execution of the turnaround, margin expansion, and revenue stabilization, while the low target of $60 prices in continued revenue decline and margin compression. Recent analyst actions show upgrades from Keybanc (to Overweight) and Mizuho (to Outperform), suggesting improving sentiment. The wide spread between low and high targets (40 points) reflects high uncertainty about the company's future performance, typical for a recently spun-off entity undergoing transformation.
Bulls vs Bears: SOLV Investment Factors
Solventum presents a mixed picture: it is a diversified healthcare company with a low valuation (trailing P/E 8.86x) and recent analyst upgrades, but it faces declining revenue, negative free cash flow, and high leverage. The bull case rests on a successful turnaround driven by operational efficiencies and digital health growth, while the bear case centers on continued revenue erosion and margin pressure. Currently, the evidence slightly favors the bull case due to the low valuation and improving momentum, but the key tension is whether the company can stabilize revenue and generate positive free cash flow. If revenue stabilizes and margins improve, the stock could re-rate higher; if not, the low P/E may be a value trap.
Bullish
- Low Valuation with Upside Potential: The trailing P/E of 8.86x is near the low end of its historical range (2.51x to 92.38x), suggesting the stock is cheap. With an average analyst target of $83.38, there is a 2.55% upside from the current price of $81.31, and the high target of $100 implies 23% upside.
- Recent Analyst Upgrades Signal Confidence: Keybanc upgraded to Overweight and Mizuho to Outperform, reflecting improving sentiment. The consensus recommendation is 'buy' with a mean score of 2.33 (1=strong buy, 5=sell), indicating broad analyst optimism about the turnaround.
- Strong Short-Term Momentum: The stock has gained 9.05% in the last month and 15.37% in the last three months, outperforming the S&P 500 by 8.74% and 10.70% respectively. This momentum suggests growing investor confidence in the company's recovery.
- Diversified Healthcare Portfolio: Solventum operates across MedSurg, Dental, and Health Information Systems, with established brands in wound therapy, orthodontics, and clinical software. This diversification reduces reliance on any single segment and provides multiple growth avenues.
Bearish
- Declining Revenue Trend: Revenue fell from $2,161 million in Q2 2025 to $1,998 million in Q4 2025, a 7.5% decline over three quarters. Year-over-year, Q4 2025 revenue was down 3.71% from $2,075 million in Q4 2024, indicating persistent top-line pressure.
- Negative Free Cash Flow: Trailing twelve-month free cash flow is -$10 million, meaning the company is not generating enough cash to cover capital expenditures. This raises concerns about financial flexibility and the ability to invest in growth or reduce debt.
- High Leverage and Interest Burden: Debt-to-equity is 0.997, near 1:1, and interest expense was $51 million in Q4 2025, consuming a significant portion of operating income. High leverage amplifies risk if revenue continues to decline or margins compress.
- Wide Analyst Target Range Reflects Uncertainty: Analyst targets range from $60 to $100, a spread of $40 (49% of current price). This wide dispersion indicates high uncertainty about the company's future performance, typical for a recently spun-off entity.
SOLV Technical Analysis
Solventum's stock is in a recovery phase, with the 1-year price change of +10.09% indicating a modest uptrend from its lows. The current price of $81.31 sits at 78.5% of its 52-week range ($62.38 - $88.20), suggesting the stock has rebounded significantly from its low but remains below the high, implying room for further upside if momentum continues. The price is near the upper end of the range, which can signal building momentum but also potential resistance ahead. Short-term momentum is strong, with a 1-month change of +9.05% and a 3-month change of +15.37%, both outpacing the longer-term 1-year trend. This acceleration suggests growing investor confidence, possibly driven by recent earnings or strategic updates. The relative strength versus the S&P 500 is positive over 1-month (+8.74%) and 3-month (+10.70%), indicating the stock is outperforming the broader market in the near term. The 52-week low of $62.38 provides a key support level, while the 52-week high of $88.20 acts as resistance. A breakout above $88.20 would signal a new uptrend and potential for further gains, while a breakdown below $62.38 could indicate a return to weakness. The beta of 0.716 indicates the stock is less volatile than the market, which may appeal to risk-averse investors but also limits upside in strong market rallies.
Beta
0.72
0.72x market volatility
Max Drawdown
-27.5%
Largest decline past year
52-Week Range
$62-$88
Price range past year
Annual Return
+8.1%
Cumulative gain past year
| Period | SOLV Return | S&P 500 |
|---|---|---|
| 1m | +5.1% | -0.6% |
| 3m | +14.9% | +5.4% |
| 6m | -1.4% | +8.3% |
| 1y | +8.1% | +18.3% |
| ytd | +0.3% | +8.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SOLV Fundamental Analysis
Revenue has been declining, with the most recent quarterly revenue of $1,998 million (Q4 2025) down 3.71% year-over-year from $2,075 million in Q4 2024. The multi-quarter trend shows revenue falling from $2,161 million in Q2 2025 to $1,998 million in Q4 2025, indicating deceleration. The MedSurg segment, which generates the majority of revenue, is likely the primary driver, but the decline suggests headwinds in core markets. The company is profitable, with net income of $63 million in Q4 2025 and a net margin of 3.15%. Gross margin has been relatively stable around 49-54% over recent quarters, with Q4 2025 at 49.3%, slightly below the prior year's 53.9%. Operating margin was 83.98% in Q4 2025, but this is inflated by a large negative other expense line; normalized operating margin is likely lower. The company's profitability is under pressure from declining revenue and high interest expenses ($51 million in Q4 2025). The balance sheet shows a debt-to-equity ratio of 0.997, indicating moderate leverage. Free cash flow was $32 million in Q4 2025, but trailing twelve-month free cash flow is negative at -$10 million, suggesting the company is not generating enough cash to cover capital expenditures. ROE is 30.82%, which is high but partly due to leverage. The current ratio of 1.23 indicates adequate liquidity, but the negative FCF trend is a concern for financial health.
Quarterly Revenue
$2.0B
2025-12
Revenue YoY Growth
-3.7%
YoY Comparison
Gross Margin
49.3%
Latest Quarter
Free Cash Flow
$-10000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SOLV Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 8.86x, while the forward P/E is 11.47x, implying the market expects earnings to decline or normalize from current levels. The gap between trailing and forward P/E suggests that recent earnings may be temporarily elevated or that the market is pricing in lower future earnings. Compared to the industry average (not provided), the P/E of 8.86x appears low, but without sector data, a direct comparison is limited. However, the P/S ratio of 1.66x and EV/EBITDA of 7.04x suggest the stock is reasonably valued relative to sales and cash earnings. Historically, the trailing P/E has ranged from 2.51x (Q3 2025) to 92.38x (Q4 2024), with the current 8.86x near the lower end of the range, indicating the stock is cheap relative to its own history. This low P/E could reflect skepticism about earnings sustainability or a value opportunity if the company can stabilize revenue and improve margins.
PE
8.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 3x~37x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
7.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Solventum's primary financial risk is its declining revenue, which fell 3.71% YoY in Q4 2025 to $1,998 million, and negative trailing free cash flow of -$10 million. The company carries a debt-to-equity ratio of 0.997, with interest expenses of $51 million in Q4 2025, which pressures net income. Gross margin has slipped from 53.9% in Q4 2024 to 49.3% in Q4 2025, indicating cost pressures or unfavorable mix. These factors suggest limited financial flexibility and reliance on cost-cutting to maintain profitability.
Market & Competitive Risks: The stock's beta of 0.716 indicates lower market correlation, but it is still exposed to macro headwinds that could slow healthcare spending. The wide analyst target range ($60-$100) reflects high uncertainty, and the stock trades at a forward P/E of 11.47x, which could compress if earnings disappoint. Competitive risks include disruption in MedSurg from new wound care technologies and pricing pressure in dental supplies. As a recent spin-off, the company lacks a long-term track record, making it vulnerable to sector rotation away from healthcare.
Worst-Case Scenario: If revenue continues to decline and margins compress further, the stock could fall to its 52-week low of $62.38, representing a 23.3% downside from the current price of $81.31. This scenario could be triggered by a major customer loss, failed product launches, or a broader economic downturn. In such a case, the P/E could contract to 6-7x, consistent with the low end of its historical range.